Adjuvant Hormone Therapy Affects OS in HR+/HER2- BC Without Chemotherapy
While the detrimental effects of delaying surgery or chemotherapy on overall survival (OS) following a breast cancer (BC) diagnosis is clear, more obscure are the effects of delaying the use of adjuvant hormone therapy in patients with hormone receptor–positive (HR+)/human epidermal growth receptor 2–negative (HER2-) early BC who have not undergone chemotherapy. Read more.

Health of Women Study on BC Risk, Diagnosis, and Treatment
The Health of Women Study was a collection of cross-sectional, web-based modules designed to survey a large number of Internet participants with and without a diagnosis of breast cancer (BC). Its purpose was to assess potential risk factors for BC and to gather information related to BC diagnosis, treatment, and the development of adverse sequalae. Read more.

Risk of Interstitial Lung Disease With CDK 4/6 Inhibitors
The arrival of the cyclin-dependent kinase (CDK 4/6) inhibitors offered new hope for patients with advanced hormone receptor–positive/human epidermal growth factor receptor-2–negative breast cancer. However, clinical regulatory trials designed to secure drug approval demonstrated the occurrence of a few severe and fatal cases of interstitial lung disease/pneumonitis that were attributed to the use of these agents. Read more.